Cargando…
Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects
BACKGROUND: Due to the high comorbidity of diabetes and hypertension, co-administration of metformin with anti-hypertensive drugs is likely. Baxdrostat is an aldosterone synthase inhibitor in development for the potential treatment of hypertension. In vitro data indicated that baxdrostat inhibits th...
Autores principales: | Freeman, Mason W., Bond, Mary, Murphy, Brian, Hui, James, Isaacsohn, Jonathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930700/ https://www.ncbi.nlm.nih.gov/pubmed/36790596 http://dx.doi.org/10.1007/s40256-023-00572-x |
Ejemplares similares
-
Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers
por: Freeman, Mason W., et al.
Publicado: (2022) -
The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension
por: Forzano, Imma, et al.
Publicado: (2022) -
Pharmacokinetics and Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Study
por: Shi, Ping, et al.
Publicado: (2021) -
Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects
por: Hanboonkunupakarn, Borimas, et al.
Publicado: (2014) -
Pharmacokinetics and bioequivalence of sunitinib and Sutent(®) in Chinese healthy subjects: an open-label, randomized, crossover study
por: Wang, Yanli, et al.
Publicado: (2023)